Determinants of Survival of HIV Patients Receiving Dolutegravir: A Prospective Cohort Study in Conflict-Affected Bunia, Democratic Republic of Congo - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36011850/
This study aims to determine the factors influencing HIV-related mortality in settings experiencing continuous armed conflict atrocities. In such settings, people living with HIV (PLHIV), and the partners of those...
Conclusions: Improving baseline viral load monitoring, starting ART early in individuals with high baseline viral loads, the proper tailoring of ART regimens and optimizing long-term ART, and care to manage non-AIDS-related chronic complications are recommended actions to reduce mortality. Not least, fostering women's inclusion, justice, peace,...
HIV-1 RNA levels in rectal and seminal compartments after switching to long-acting cabotegravir plus rilpivirine: a longitudinal study
You do not currently have access to this article. Don't already have an Oxford Academic account? Register HIV-1 RNA levels in rectal and seminal compartments after switching to long-acting cabotegravir...
/>
Conclusions:. Maintenance of viral suppression in rectal and seminal compartments was comparable and blips occurred with similar frequency with both treatment regimens.
Effect of Rifabutin in Dolutegravir Dosing: A Case Series - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36026587/
Background: Tuberculosis (TB) is the leading cause of death in human immunodeficiency virus (HIV)-infected people worldwide. Currently there are no studies examining the use of Rifabutin (RBN) and Dolutegravir (DTG)...
Conclusions: Given the frequency of low DTG and RBN concentrations, therapeutic drug monitoring (TDM) for these drugs is advisable. Prospective clinical studies are needed to further determine the PK interactions between RBN and DTG, and virologic response to treatment.
In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV - Scientific Reports
Source : https://www.nature.com/articles/s41598-022-18009-x
Dolutegravir (DTG) is an antiretroviral drug approved in the year 2013, and being categorized as a BCS-II molecule, it possesses solubility issues. In order to enhance the solubility and improve...
Conclusion: Altogether, the research findings showed that Chitosan-based NPs were ideal carriers for oral administration of DTG along with milk and exhibited great potential to enhance the bioavailability of the drug and treatment adherence for paediatric HIV patients.
A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, | POR
Human Immunodeficiency Virus Type 1 (HIV-1) remains a global health problem with an estimated 37.6 million people globally living with HIV-1 in 2020. Most of these cases were reported from...
Conclusion: This study demonstrated the safety and efficacy of DTG based regimen in treatment naïve HIV-1 patients in Indian population and support use of DTG as first-line treatment regimen.